#United States #San Juan #AbbVie #ELAHERE #OvarianCancer

AbbVie Showcases Late-Breaking Data for ELAHERE® in Ovarian Cancer

AbbVie recently announced the presentation of late-breaking results from the Phase 2 IMGN853-0420 trial during the Society of Gynecologic Oncology (SGO) Annual Meeting held from April 10-13 in San Juan, Puerto Rico. This groundbreaking study focuses on mirvetuximab soravtansine-gynx (marketed as ELAHERE®), an innovative antibody-drug conjugate intended for patients battling platinum-sensitive ovarian cancer (PSOC) expressing the folate receptor alpha (FRα).

The trial's data are showing a noteworthy objective response rate (ORR) of 62.7% among patients treated with ELAHERE® combined with carboplatin, followed by a continued monotherapy with ELAHERE®. This study specifically targeted individuals with at least 50% expression of FRα, which can play a critical role in how effectively cancer cells respond to this novel treatment.

Trial Overview

The IMGN853-0420 trial was a multicenter, open-label study that involved 125 participants. All subjects had previously undergone at least one platinum-based chemotherapy course, and the aim was to evaluate the safety and efficacy of the combination therapy. The primary endpoint was the confirmed ORR after just six cycles of treatment, while secondary endpoints included duration of response (DoR) and progression-free survival (PFS).

The results indicate that nearly half of the participants had prior exposure to a polymerase inhibitor (PARPi), a factor that can complicate responses to subsequent platinum-based treatments. This population has historically been challenging to treat, making the findings from this study particularly significant.

Efficacy and Safety Findings

Results from the trial indicated that after the sixth cycle of treatment, an ORR of 62.7% was confirmed in the FRα ≥50% subgroup, with an impressive 81% of patients showing no sign of disease progression. The median duration of response recorded was 11.2 months.

Further positive outcomes emerged for those who transitioned to monotherapy with mirvetuximab soravtansine-gynx. An ORR of 68% was recorded within the overall study population in this phase. Notably, for the 49% of patients who had previously been treated with a PARPi, an ORR of 63.9% was observed, further underscoring the treatment's potential efficacy.

The safety profile aligned with prior study findings for mirvetuximab soravtansine-gynx. For the combination treatment, common treatment-related adverse events included low-grade ocular issues, with over 90% of patients experiencing reversible corneal changes. More serious complications were monitored, including neutropenia and blurred vision, which occurred at rates exceeding 5%.

Dr. Daejin Abidoye, Vice President and Oncology Head at AbbVie, commented on the encouraging results, highlighting that despite being categorized as chemotherapy-responsive, patients often struggle with cumulative toxicities and diminishing responses during treatment for PSOC. He pointed out that ELAHERE® presents a promising new approach to treatment.

Future Directions

The study's findings were presented during a Rapid-Fire Oral session, emphasizing the need for novel treatment strategies for PSOC, particularly those integrating antibody-drug conjugates with standard chemotherapy. The ongoing investigation signals a commitment to improving outcomes for patients previously treated with PARP inhibitors, who often find themselves facing treatment resistance.

While ELAHERE® has shown promising results in clinical trials, it's critical to remember that it has yet to gain approval in the U.S. or EU for this combination therapy. Abbvie continues its dedication to exploring effective treatment options for patients suffering from difficult-to-treat cancers as part of its broader oncology strategy.

For more details about AbbVie’s clinical trials and ongoing research, visit clinicaltrials.gov. As research progresses, the medical community remains hopeful for effective therapies that improve patient outcomes and quality of life in the ongoing battle against ovarian cancer.